Insulin-dependent diabetes meilitus (IDDM) is thought to result from the autoimmune destruction of the insulin-producing ft cells of the pancreas. Years before IDDM symptoms appear, we can detect autoantibodies to one or both forms of glutamate decarboxylase (GAD6% and GAD67), synthesized from their respective cDNAs in a bacterial expression system. Individual IDDM sera show distinctive profiles of epitope recognition, suggesting different humoral immune responses. Although the level of GAD autoantibodies generally decline after IDDM onset, patients with IDDM-associated neuropathies have high levels of antibodies to GAD, years after the appearance of clinical IDDM. We note a striking sequence similarity between the two GADs and Coxsackievirus, a virus that has been associated with IDDM both in humans and in experimental animals. This similarity suggests that molecular mimicry may play a role in the pathogenesis of IDDM. (J. Clin. Invest. 1992. 89:283-292.)
Introduction
Insulin-dependent diabetes (IDDM;' type I diabetes) is one of the most serious and common ofmetabolic disorders, affecting approximately 1 person in 300 in the U.S., while epidemiological studies in Europe suggest that its incidence is increasing (reviewed in 1-3). The disease is thought to result from the autoimmune destruction ofthe insulin-producing ( cells ofthe pancreas and the subsequent metabolic derangements. Al-though insulin therapy allows most patients to lead active lives, this replacement is imperfect since it does not restore normal metabolic homeostasis. Metabolic abnormalities are thought to be important in the subsequent development of common complications, which include retinopathy, cataract formation, nephropathy, neuropathy, and heart disease.
While the initiating agent of IDDM autoimmunity is not known, it ultimately provokes a loss of immunological tolerance to self-antigens present in insulin-secreting (3 cells within the pancreatic islets (4) (5) (6) . IDDM begins with an asymptomatic stage, characterized by a chronic inflammatory infiltrate of the islets (insulitis), which selectively destroys the (3cells. Only after the destruction of the majority of the (3 cells, often occurring over several years, do hyperglycemia and ketosis appear.
The pathogenesis ofIDDM involves both genetic and environmental factors. One or more susceptibility factors are encoded by the major histocompatibility complex on chromosome 6, probably by the DQ Al and Bl loci (7, 8) . Studies of monozygotic twins, however, show a concordance for IDDM of < 40%, suggesting that environmental factors play an important role (9) . Long suspected environmental causes of IDDM include a number of viruses, such as rubella, encephalomyocarditis virus, and especially Coxsackie virus B4 (reviewed in 10-12).
Autoantibodies to a 64,000 Mr islet cell protein are associated with IDDM and have been detected years before the onset of symptoms (13) (14) (15) . Other IDDM-associated autoantibodies, such as those against insulin and cytoplasmic gangliosides ofislet cells (ICA), appear later, possibly as a consequence of the release of these antigens (or their precursors) from the damaged islet cells (16, 17) . Antibodies to the 64,000 M, proteins are, however, the earliest and most reliable predictive marker of IDDM in humans and are also present in the two animal models for IDDM, the nonobese diabetic (NOD) mouse and the Biobreeding rat (14, 15, 18, 19) .
Baekkeskov et al. (20) reported that the 64,000 Mr islet cell autoantigen is a form of glutamate decarboxylase (GAD; E.C. 4.1.1.15), the enzyme responsible for the synthesis of y-aminobutyric acid (GABA) in brain, peripheral neurons, pancreas, and other organs (21) . We have recently shown that the brain contains two forms of GAD, which are encoded by two separate genes (22) . The two GADs (GAD65 and GAD67) differ in molecular size (with Mrs = 65,000 and 67,000) and amino acid sequence (with -30% sequence divergence), as well as in their intracellular distributions and interactions with the GAD cofactor pyridoxal phosphate (22) (23) (24) (25) . In brain neurons, GAD65 is preferentially associated with axon terminals, while GAD67 is present in both terminals and cell bodies (25) .
proteins. In view of our demonstration that the brain contains two GADs, we set out to determine the molecular identity of islet cell GAD by immunohistochemistry with monospecific antibodies. We then used GAD65 and GAD67 produced in genetically engineered bacteria from our GAD cDNAs to examine the specificity of IDDM autoantibodies for the two GADs and for restricted sets of GAD epitopes.
Our results lead to two new suggestions concerning the pathogenesis ofIDDM and its complications: (a) GAD autoimmunity may play a role in the pathogenesis of IDDM-associated neuropathies; and (b) IDDM autoimmunity may result from molecular mimicry of GAD and a Coxsackievirus peptide.
Methods
Patient sera. IDDM patients and individuals at high risk forlater developing IDDM were selected from a previous study at the University of Florida Diabetes Clinics (15, 26) . IDDM patients with peripheral neuropathies were selected from the University ofFlorida Diabetes Clinics and the UCLA Diabetes Clinic.
Nondiabetic controls and the individuals studied before the documented clinical onset were ascertained through ongoing prospective screening for islet cell antibodies of more than 5,000 first-degree relatives ofIDDM probands, and 8, 200 Immunohistochemistry. Immunochemical detection of the two forms of GAD was performed as previously described for rat cerebellum (25) .
Antigen preparation and immunoadsorption. Rat GAD65 and GAD67 cDNAs were subcloned in the NcoI site ofpET 8C and the Nhe I site of pET-SC respectively and transformed into Escherichia coli BL21 (DE3) (20, 27) . Control and GAD-producing E. coli were grown and induced with isopropyl-thio-fl-D-galactoside, harvested by centrifugation, resuspended in GAD buffer, sonicated, and cleared by centrifugation at 55,000 g for 15 min. For immunocompetition, 30 M1 of each patient serum was incubated with 100 ul ofextract from control bacteria or from bacteria that produced either GAD65 or GAD67 for 1 h at 4°C. Human pancreatic islets were labeled with 35-methionine as previously described (15 (20) . The three high-risk individuals whose sera we examined had high anti-GAD titers, in one case comparable to those raised against purified brain GAD in experimental animals (data not shown). The levels of antibodies to GAD in five of eight newly diagnosed patients exceeded the mean + 1 SD of the control sera. Levels in these patients decreased by -50% during the subsequent two years, with only two of seven sera having levels more than the mean + 1 SD of the control sera. In most patients 2 6 years after diagnosis, the concentrations of antibodies to GAD were indistinguishable from controls. In one patient in this series, however, anti-GAD levels actually rose between 6 and 11 years after onset, during which time the patient developed a sensory neuropathy.
Levels of anti-GAD antibodies in these patients generally parallel the previously determined titers of autoantibodies to the 64,000 M, antigen. Our assays of immunoprecipitated GAD enzymatic activity easily identified individuals with high titers of autoantibodies to the 64,000 Mr antigen, but did not often distinguish individuals with low titers from controls.
This study established that autoantibodies to GAD are present at and before the clinical diagnosis of IDDM and decline within a few years after diagnosis. We next addressed the question of the molecular identity of the GAD autoantigen.
Islet cells contain both GAD65 and GAD67. Immunohistochemical experiments with the GAD-6 monoclonal antibody, which recognizes only GAD65, show the presence of GAD65 in pancreatic islets ( Fig. 2 ; references 20, 25, 30) . Using our recently described K-2 antiserum, which recognizes only GAD67, we show that islet cells also contain GAD67 ( Fig. 2 ; reference 25). Since both GAD65 and GAD67 are present in islets, either or both could be the autoantigen recognized by the IDDM sera surveyed in Fig. 1 and by Baekkeskov et al. (20) .
The 64,000 Mr islet cell autoantigen is GAD65. To define further the molecular identity of the IDDM autoantigen, we performed two sets of experiments. In the first experiment we used GAD-6 (the GAD65-specific monoclonal antibody) to immunoadsorb GAD65 both from detergent extracts of 35S-labeled islet cells and from soluble extracts of 35S-labeled GADproducing bacteria. GAD-6 specifically recognized a 65,000 M, immunoreactive polypeptide in both islet cells and GAD65-producing bacteria with identical electrophoretic mobilities, which were distinct from bacterially produced GAD67. Prior immunoadsorption with an IDDM serum removes immunoreactive GAD65 (i.e., "64K") from both islet cell and bacterial extracts (data not shown).
In the second set ofexperiments, we examined the ability of bacterially produced GAD65 and GAD67 to compete with the immunoadsorption of islet cell autoantigens by IDDM sera. Sera taken from two patients (patient 052 and 496 which recognize both GADs; see Table I The sera ofNOD mice also show immunoreactivity both to GAD65 and to GAD67 (Fig. 4, lane 22) . This finding further underscores the similarity of the disease processes in human IDDM and in NOD mice.
Individual sera vary in epitope recognition. To examine the individual variability in epitope recognition ofIDDM autoantibodies, we determined the ability of sera from four individuals to recognize three polypeptide segments of GAD65 (Fig. 5) the onset of diabetic symptoms (Table I ; Fig. 4, lanes 18-21) . Six of the sera examined had detectable levels of autoantibodies to both GAD65 and GAD67, while two had detectable autoantibodies only to GAD67. Two patients with rapidly progressing autonomic neuropathies (UCI and UC2) had especially high levels of autoantibodies to GAD. In contrast, none of the nine patients who were free ofIDDM-associated complications examined at or more than five years after onset had detectable antibodies to GAD. The GAD autoantibodies in neuropathy patients may result from the restimulation of the immune system by GAD released from damaged neurons, or they may be involved in the actual pathogenesis of this complication. In either case, GAD autoantibodies may serve as a useful marker of an ongoing degenerative process.
Sequencesimilarities between GAD andCoxsackievirus. Although we observe high levels ofautoantibodies to GAD before IDDM onset, their presence may merely reflect an immune reaction to the exposure ofpreviously sequestered antigens following ,B cell damage. Indeed, the initiating agent of the autoimmune response in IDDM is completely unknown, though the increasing incidence ofIDDM and its frequent discordance in monozygotic twins has led to the suggestion that an environmental agent triggers autoimmunity (31, reviewed in 3, 12) . In other autoimmune diseases, pathogenesis is thought to involve "molecular mimicry," in which a bacterial or viral antigen triggers an immune response that then reacts with a similar self antigen (reviewed 4, 32, 33).
Analysis of the deduced amino acid sequences of GAD65
and GAD67 shows an extensive and surprising sequence similarity to the P2-C protein ofCoxsackievirus B4. Coxsackievirus B4 is a picornavirus with a worldwide distribution. It causes a mild upper respiratory infection and can also infect f, cells (reviewed in 10-12). It has a small genome (7,395 bases), and its P2-C protein appears to contribute to the membrane-bound replication complex (34) . A core polypeptide segment of six amino acid residues is identical in sequence between GAD65 and P2-C ( (lanes 1-3) in the positions ofcharged residues. In the 24 residue segments ofGAD65 and P2-C that are illustrated in Fig. 6 , 19 residues are either identical or conservative differences. The three peptides shown in Fig. 6 have nearly identical hydrophobicity profiles (data not shown). The high charge density and the presence ofa proline residue in the shared core suggest that the segments are highly antigenic. No other significant similarities were found between GAD and other viruses implicated in IDDM, such as rubella, mumps, encephalomyocarditis virus, and cytomegalovirus. A generally similar sequence similarity is also present in the P2-C region of other members of the Coxsackievirus family. Ifspecific members ofthe Coxsackievirus family (such as B4 and B5) are indeed involved in the etiology of IDDM, their pathogenicity may involve factors such as their particular amino acid sequences, virulence, and cell trophism, as well as the host immune repertoire.
Discussion
In a blind clinical study, we tested IDDM sera for the presence of GAD autoantibodies by their ability to immunoprecipitate GAD enzymatic activity from brain homogenates. We found the highest levels ofGAD autoantibodies in individuals at high risk for IDDM and in newly diagnosed IDDM patients. Levels of GAD autoantibodies decreased by 50% within two years after diagnosis. Six years after IDDM onset, the patients whose sera we examined had GAD autoantibody levels indistinguishable from controls. One patient, however, displayed increased GAD antibodies years after onset, during which time the patient developed a sensory neuropathy. Our studies of GADs in the brain have shown that neurons express two forms of GAD, which derive from separate genes (22) . Pancreatic ,B cells also express GAD and use GABA to regulate glucagon secretion by a cells (35) . Our immunohistochemical data, using antibodies monospecific for GAD65 and GAD67, show that ( cells, like most GABA neurons, contain both GAD65 and GAD67. Although our enzymatic studies, and those ofBaekkeskov et al. (20) , demonstrated GAD autoimmunity in IDDM, they did not distinguish the two forms ofGAD.
We used GAD65 and GAD67 cDNAs to express large amounts of each GAD in a bacterial expression system and tested the ability ofeach form to compete with the immunoadsorption of the 64,000 Mr autoantigen from 35S-labeled islet cells. Only GAD65-containing lysates effectively competed, suggesting that the 64,000 Mr autoantigen corresponds to GAD65.
The islet cell homogenates previously used to characterize IDDM autoantigens were enriched for membrane-associated molecules and may preferentially have included GAD65. In contrast, both our studies of the soluble fraction and those of Christie et al. (36) show a complex pattern of antigens recognized by IDDM autoantibodies (data not shown). Since islet cells contain both GAD65 and GAD67, (Fig. 2) we sought to characterize the GAD autoantibodies by testing the ability of IDDM sera to recognize bacterially produced GAD65 and GAD67.
We could detect autoantibodies to either GAD65 or GAD67 or both in almost all people who later developed IDDM, in some cases years before the onset of clinical symptoms. Of 23 early stage IDDM individuals tested, we found antibodies to both GADs in 15, to GAD65 alone in 3, and to GAD67 alone in 4. By testing for antibodies to both forms ofGAD we were able to detect GAD antibodies in 96% of the individuals tested. acid residues with similar charge, polarity, or hydrophobicity. Numbers refer to the amino acid residues in GAD65, GAD67, and Coxsackievirus protein P2-C. The human GAD amino acid sequences, which are almost identical to the rat GAD sequences, were determined by Bu Dingfang et al. (manuscript submitted for publication).
Levels of GAD autoantibodies were usually highest before IDDM onset and, in our patient sample, appeared as early as five years before onset of symptoms. GAD antibody levels declined after onset, presumably in parallel with the loss ofGADcontaining ( cells and the extinction ofantigen-driven autoimmunity.
Patient$ showed varying immunoreactivity to GAD65 and GAD67, which share -70% amino acid similarity and are most divergent at their amino termini (22 Fig. 5 ), the antibodies may recognize GAD epitopes different from those that originally activated T lymphocytes.
Because our initial survey of IDDM patients detected increased levels of GAD autoantibodies in a patient who developed a sensory neuropathy long after the onset of diabetes itself, we further studied GAD autoimmunity in patients with IDDM-associated neuropathies. We found that 8/9 patients who had developed clinical IDDM symptoms 10-41 years earlier, showed significant levels of autoantibodies to GAD65, GAD67, or both. Of the eight patients in this group for whom we had ICA data, none had detectable ICA, and their low basal C-peptide did not respond to intravenous glucagon, suggesting that the continued high levels of anti-GAD autoantibodies did not result from the persistence of GAD-containing ,B cells.
The production of anti-GAD autoantibodies in patients with diabetic neuropathy may reflect continued stimulation of the immune system by GAD in the peripheral nervous system. Consistent with this hypothesis, Rabinowe et al. (37) have shown that, in some IDDM patients, autoantibodies to sympathetic ganglia are present at the diagnosis of IDDM, before the onset ofclinical neuropathy. In addition, postmortem examination has revealed lymphocytic infiltration of sympathetic ganglia in IDDM patients with autonomic neuropathy (38) . Our data suggest that autoimmunity to GAD, together with the metabolic effects of hyperglycemia, may play an important pathogenic role in diabetic neuropathy in IDDM.
The surprising similarity of the amino acid sequences of GAD65 and GAD67 to the P2-C protein of Coxsackievirus suggests that IDDM autoimmunity may arise by molecular mimicry, as a consequence ofinfection by Coxsackievirus. Epidemiological studies have shown that 39% of newly diagnosed IDDM patients have IgM responses to Coxsackievirus, compared to 6% of controls (39, 40) . The molecular mimicry hypothesis suggests a mechanism to explain both the epidemiological association of Coxsackievirus B4 with human IDDM and its ability (in contrast to other viruses epidemiologically associated with IDDM) to produce diabetes in mice and primates (31, (41) (42) (43) (44) 
I
F P E V K T K (49) . Autoantibodies to GAD are the earliest indication ofautoimmunity in IDDM and the two GADs are therefore excellent candidates for the initial targets for autoimmunity. Future experiments will determine whether the epitope shared by GAD and Coxsackievirus contributes to IDDM pathogenesis. If GAD is indeed involved in the etiology of IDDM, it may be possible to devise specific, rather than nonspecific, immunosuppressive strategies to block the function of specific MHC and T cell receptor molecules.
